Effect of Warfarin and Shensong Yangxin Capsule in the Treatment of Atrial Fibrillation and Its Effect on Serum MMP-2 and hs-CRP Levels
Dang Ya'nan
Dang Yadong
Abstract：Objective To investigate the clinical effect of warfarin and Shensong Yangxin capsule (SYC) in the treatment of atrial fibrillation (AF) and its effect on serum levels of matrix metalloproteinase 2 (MMP-2) and high sensitive C-reactive protein (hs-CRP) in patients.Methods One hundred and fifty patients with AF treated in our hospital from January 2015 to December 2016 were selected,and randomly divided into two groups: control group treated with warfarin,and observation group treated with warfarin and SYC.The clinical efficacy and the incidence of atrial fibrillation before and after treatment,the levels of serum MMP-2,hs-CRP and adverse reactions were observed.Results After the treatment of 12 weeks,the total effective rate in observation group was higher than that in control group (P<0.05).After treatment,the seizure frequency and duration in two groups were significantly lower than those before treatment (P<0.01),which was better in observation group than that in control group (P<0.01).Compared with those before treatment,the levels of MMP-2 and hs-CRP were significantly decreased in two groups after the treatment of 12 weeks (P<0.01),which was better in observation group than that in control group (P<0.01).There was no obvious adverse reactions in two groups.Conclusion Warfarin and SYC can effectively reduce or eliminate the symptoms and improve the disease in patients with AF.The curative effect is significant and safe.
Keywords：atrial fibrillationShensong Yangxin capsulewarfarinhigh sensitive C-reactive proteinmatrix metalloproteinase 2
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 2101-2103 )